Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Indian J Endocrinol Metab. 2012 Jan;16(1):33-43. doi: 10.4103/2230-8210.91183.

Preventive pharmacotherapy in type 2 diabetes mellitus.

Author information

  • 1Department of Medicine, Goodhealth Clinic, New Delhi, India.

Abstract

Over the last few decades certain demographic changes have been observed worldwide, which have led to an increase in the prevalence of chronic non-communicable diseases. Type 2 diabetes mellitus and associated cardiovascular disease are major contributors to this disease burden leading to rising morbidity and mortality. It is worrisome to see that type 2 diabetes with its micro- and macrovascular complications is occurring in younger populations where it was hitherto unseen. Prevention appears to be an important strategy to reduce the burden of disease. Along with inculcating healthy lifestyle habits across populations, it may be suitable to use preventive pharmacotherapy in those with pre-diabetes and / or other risk factors like obesity, hypertension, and on the like. Metformin, alpha glucosidase inhibitors like acarbose, miglitol, and voglibose, and pioglitazone have all been used with success. The issues of compliance and adverse effects during long-term use have tempered the use of these drugs. The best approach would be to motivate the patient for effective lifestyle changes, and pharmacological management if the lifestyle changes are not successful in achieving their goals.

KEYWORDS:

Acarbose; metformin; pharmacotherapy; pioglitazone; prevention; type 2 diabetes mellitus; voglibose

PMID:
22276251
[PubMed]
PMCID:
PMC3263195
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Write to the Help Desk